Literature DB >> 26014109

Opposing effects of glutamatergic and GABAergic pharmacological manipulations on a visual perception task with relevance to schizophrenia.

John C Talpos1, John Riordan2, Joseph Olley2, Jason Waddell3, Thomas Steckler2.   

Abstract

RATIONALE: Numerous psychiatric disorders and neurodegenerative diseases have been associated with differences in visual perception, and it has been proposed that the treatment of these differences may represent a novel means to treat disorders like schizophrenia. Unfortunately, few methods exist to study visual perception in pre-clinical species.
OBJECTIVE: The purpose of the present study was to adapt a task of visual integration by proximity with relevance to schizophrenia to a rodent touchscreen environment to determine the effects of glutamatergic and GABAergic compounds. In this way, we could evaluate the effects of common models of cognitive impairment, as well as the effects of net excitation versus inhibition, on a task of visual integration.
METHOD: Rats were trained to perform a visual discrimination where the stimuli were composed of rows of dots differing only in there horizontal and vertical proximity. Once stable performance had been achieved, animals were tested under the influence of glutamatergic or GABAergic drugs (ketamine, MK-801, PCP, memantine, chlordiazepoxide, or diazepam) while attempting to perform a visual discrimination with altered stimuli.
RESULTS: Ketamine appeared to impair perceptual grouping in this paradigm, while the GABA agonist chlordiazepoxide enhanced grouping even in the presence of non-selective effects.
CONCLUSIONS: In general, these findings support the theory that NMDA antagonists may disrupt visual grouping by proximity and highlight a potential beneficial effect of enhanced GABA activity in perception. However, additional research will be required to confirm the stimulus selectivity of this effect, and the clinical significance of this approach.

Entities:  

Keywords:  Autism; NMDA receptor; Rat; Schizophrenia; Touchscreen; Visual cortex; Visual integration

Mesh:

Substances:

Year:  2015        PMID: 26014109     DOI: 10.1007/s00213-015-3964-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  Perceptual grouping in disorganized schizophrenia.

Authors:  Peter J Uhlhaas; William A Phillips; Gordon Mitchell; Steven M Silverstein
Journal:  Psychiatry Res       Date:  2006-11-01       Impact factor: 3.222

Review 2.  Visual impairment in Alzheimer's disease: a critical review.

Authors:  Elizabeth Kirby; Stephan Bandelow; Eef Hogervorst
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Temporal integration of 3D coherent motion cues defining visual objects of unknown orientation is impaired in amnestic mild cognitive impairment and Alzheimer's disease.

Authors:  Raquel Lemos; Patrícia Figueiredo; Isabel Santana; Mário R Simões; Miguel Castelo-Branco
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli.

Authors:  J C Talpos; A C Fletcher; C Circelli; M D Tricklebank; S L Dix
Journal:  Psychopharmacology (Berl)       Date:  2011-11-26       Impact factor: 4.530

5.  Perceptual grouping abilities in individuals with autism spectrum disorder; exploring patterns of ability in relation to grouping type and levels of development.

Authors:  Emily K Farran; Mark J Brosnan
Journal:  Autism Res       Date:  2011-05-23       Impact factor: 5.216

Review 6.  Cognitive explanations of autism.

Authors:  U Frith
Journal:  Acta Paediatr Suppl       Date:  1996-10

Review 7.  Elucidating the neurophysiological underpinnings of autism spectrum disorder: new developments.

Authors:  C Luckhardt; T A Jarczok; S Bender
Journal:  J Neural Transm (Vienna)       Date:  2014-07-25       Impact factor: 3.575

8.  Perceptual organization by proximity and similarity in schizophrenia.

Authors:  Daniel D Kurylo; Roey Pasternak; Gail Silipo; Daniel C Javitt; Pamela D Butler
Journal:  Schizophr Res       Date:  2007-07-27       Impact factor: 4.939

9.  Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints.

Authors:  Shannon L Risacher; Darrell Wudunn; Susan M Pepin; Tamiko R MaGee; Brenna C McDonald; Laura A Flashman; Heather A Wishart; Heather S Pixley; Laura A Rabin; Nadia Paré; Jessica J Englert; Eben Schwartz; Joshua R Curtain; John D West; Darren P O'Neill; Robert B Santulli; Richard W Newman; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2012-10-18       Impact factor: 4.673

Review 10.  Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS.

Authors:  Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

View more
  1 in total

1.  Analysis of vertebrate vision in a 384-well imaging system.

Authors:  Robert J Thorn; Amanda Dombroski; Kerry Eller; Tania M Dominguez-Gonzalez; Danielle E Clift; Peter Baek; Renee J Seto; Elizabeth S Kahn; Sara K Tucker; Ruth M Colwill; Jason K Sello; Robbert Creton
Journal:  Sci Rep       Date:  2019-09-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.